debrisoquin has been researched along with encainide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Funck-Brentano, C; Roden, DM; Turgeon, J; Woosley, RL | 1 |
| Altenbern, D; Dai, GH; Oates, J; Roden, DM; Wang, T; Wilkinson, GR; Woosley, RL | 1 |
| Dorne, JL; Renwick, AG; Slob, W; Walton, K | 1 |
1 trial(s) available for debrisoquin and encainide
| Article | Year |
|---|---|
Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.
Topics: Adult; Anilides; Biological Availability; Debrisoquin; Drug Interactions; Electrocardiography; Encainide; Humans; Male; Metabolic Clearance Rate; Middle Aged; Polymorphism, Genetic; Quinidine | 1989 |
2 other study(ies) available for debrisoquin and encainide
| Article | Year |
|---|---|
Co-inheritance of the polymorphic metabolism of encainide and debrisoquin.
Topics: Administration, Oral; Adult; Aged; Anilides; Chromatography, High Pressure Liquid; Debrisoquin; Electrocardiography; Encainide; Female; Half-Life; Humans; Isoquinolines; Kinetics; Male; Middle Aged; Phenotype | 1986 |
Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
Topics: Adult; Aged; Aging; Benzhydryl Compounds; Cresols; Cyclohexanols; Cytochrome P-450 CYP2D6; Debrisoquin; Desipramine; Encainide; Ethnicity; Genetic Variation; Humans; Hydroxylation; Infant; Infant, Newborn; Kidney Diseases; Kinetics; Liver Diseases; Metabolic Clearance Rate; Metoprolol; Phenylpropanolamine; Polymorphism, Genetic; Propafenone; Substrate Specificity; Tolterodine Tartrate; Venlafaxine Hydrochloride | 2002 |